Market Place
Sourcing Support
Moleac Announces PT Ferron Par Pharma as New Partner in Indonesia
21 Oct 2024 //
PR NEWSWIRE
Endo Issues Voluntary Nationwide Recall of Clonazepam Tablets
17 Jul 2024 //
FDA
Par Pharma recalls blood pressure med for possible contamination
22 Apr 2024 //
FIERCE PHARMA
Par Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection
12 Mar 2024 //
PR NEWSWIRE
Par`s Generic Topiramate Receives Receives Approval in the U.S.
04 May 2023 //
FDA
Par`s Generic Alvimopan Receives Approval in the U.S.
24 Jan 2023 //
FDA
Novartis pays $245M to settle Exforge generic pay-for-delay suit
04 Jan 2023 //
FIERCE PHARMA
Adderall Shortages in US Spread to Two More Drug Suppliers
20 Sep 2022 //
BLOOMBERG
Endo loses appeal challenging generic version of best-seller Vasostrict
19 Aug 2022 //
REUTERS
Enforcement Report - Week of March 16, 2022
17 Mar 2022 //
FDA
Par Pharma begins shipping of US FDA approved generic Cuvposa oral solution
06 Jan 2022 //
PHARMABIZ
Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution
04 Jan 2022 //
PRNEWSWIRE
Endo enters settlement agreement to resolve opioid claims in Texas
24 Dec 2021 //
PHARMACEUTICAL-TECHNOLOGY
Eagle Reports, Par Has Unilaterally Withdrawn Idea to Halt Launch of Vasopressin
20 Dec 2021 //
BUSINESSWIRE
Par Pharm`s Generic Everolimus Receives Approval in US
22 Oct 2021 //
FDA
Drugmaker Endo settles opioid claims by New York, counties for $50 million
09 Sep 2021 //
PRNEWSWIRE
BioDuro-Sundia plants its flag at former Par manufacturing site in CA
26 Aug 2021 //
ENDPTS
Par Pharma Abusing FDA Process To Foil Rivals, Amneal Says
03 Feb 2021 //
LAW360
Par Pharmaceutical, Inc. v. Hospira, Inc. (Fed. Cir. 2020)
30 Nov 2020 //
PATENTDOCS
Par Pharm`s Generic Chlorzoxazone Receives Approval in US
04 Nov 2020 //
FDA
Enforcement Report - Week of September 2, 2020
02 Sep 2020 //
FDA
Par Pharm`s Generic Doxepin Hydrochloride Receives Approval in US
31 Jul 2020 //
FDA
Enforcement Report - Week of April 8, 2020
08 Apr 2020 //
FDA
Enforcement Report - Week of March 25, 2020
25 Mar 2020 //
FDA
Enforcement Report - Week of February 19, 2020
20 Feb 2020 //
FDA
Par Pharm`s Generic Penicillamine Receives Approval in US
27 Dec 2019 //
FDA
Par Pharm`s Generic Zileuton Receives Approval in US
18 Dec 2019 //
FDA
Par Pharm`s Generic Everolimus Receives Approval in US
12 Dec 2019 //
FDA
Par Pharm`s Generic Erythromycin Ethylsuccinate Receives Approval in US
25 Oct 2019 //
FDA
Endo introduces generic Noxafil DR tablets in US market
04 Sep 2019 //
PHARMABIZ
Par Pharm`s Generic Sapropterin Dihydrochloride Receives Approval in US
22 Aug 2019 //
FDA
Par Pharm`s Generic Everolimus Receives Tentative Approval in US
07 Aug 2019 //
FDA
3 drugmakers dominated opioid supplies as 76B pills flooded the U.S.: report
18 Jul 2019 //
FIERCE PHARMA
Enforcement Report - Week of May 15, 2019
15 May 2019 //
FDA
Par Pharm`s Generic Sapropterin Dihydrochloride Receives Approval in US
14 May 2019 //
FDA
Par recalls product after glass particulate contamination
13 May 2019 //
IN -PHARMATECHNOLOGIST
Par Pharmaceutical recalls Mycophenolate Mofetil Injection, USP
04 May 2019 //
FDA
3M Begins Mfg. Authorized Generic Inhaler
02 May 2019 //
CONTRACT PHARMA
Par Pharma Issues Voluntary Recall of One Lot of Mycophenolate Mofetil for Inj
01 May 2019 //
PR NEWSWIRE
Novartis Pharmaceuticals Corp. v. Par Pharmaceutical Inc.
19 Apr 2019 //
PATENDOCS
Vasostrict (Vasopressin) : Par Pharmaceutical vs. Amphastar Pharmaceuticals
20 Dec 2018 //
PATENT LITIGATION
Par Pharm`s Generic Colchicine Receives Approval in US
29 Nov 2018 //
FDA
Valsartan products not currently recalled - Updated November 27, 2018
28 Nov 2018 //
FDA
Par Pharm`s Generic Midodrine Hydrochloride Receives Approval in US
01 Nov 2018 //
FDA
Vasostrict (Vasopressin) : Par Pharmaceutical vs. Sandoz Inc.
19 Oct 2018 //
PATENT LITIGATION
Par Pharm`s Generic Dofetilide Receives Approval in US
10 Oct 2018 //
FDA
Par Pharma`s Generic Topiramate Receives Tentative Approval in US
25 Sep 2018 //
FDA
Enforcement Report - Week of September 19, 2018
19 Sep 2018 //
FDA
Enforcement Report - Week of September 12, 2018
12 Sep 2018 //
FDA
Jublia (efinaconazole) : Valeant Pharma, Dow Pharmac v. Par Pharmaceutical
11 Sep 2018 //
PATENT LITIGATION
Vasostrict (Vasopressin) : Athenex Pharma Solutions v. Par Pharmaceutical Inc
18 Aug 2018 //
PATENT LITIGATION
Raviciti® (glycerol phenylbutyrate) : Horizon Therapeutics v. Par Pharmaceutical
11 Aug 2018 //
PATENT LITIGATION
Valsartan products not currently recalled - Updated August 8, 2018
09 Aug 2018 //
FDA
Shire Moves to Protect Gattex From Par Generic Challenge
31 Jul 2018 //
BLOOMBERG
Gattex (teduglutide), Amlodipine and Valsartan Tabs : Shire-NPS Pharm v. Par Pharma et al.
30 Jul 2018 //
PATENT LITIGATION
Par Pharm’s Generic Diltiazem Hydrochloride Receives Approval In US
01 Jun 2018 //
FDA
